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ABSTRACT 
Two cases of malaria by Plasmodium vivax relapsed after treatment with drugs 
in doses recommended by the Ministry of Health are presented. Both patients 
were overweight and were followed in the Federal District, an area considered 
free from vector transmission of the disease. Radical cure was obtained after 
medication with the same drugs in weight proportional doses. 
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RESUMO
São apresentados dois casos de pacientes com malária por Plasmodium 
vivax que apresentaram recaídas após tratamento com medicamentos em 
doses indicadas pelo Ministério da Saúde. Ambos os pacientes tinham pesos 
elevados e foram acompanhados no Distrito Federal, área considerada sem 
transmissão vetorial da doença. A cura radical foi obtida após medicação em 
dose proporcional ao peso corpóreo dos pacientes.
Palavras-chaves: Malária vivax. Primaquina. Recaídas. 
It is common practice in Brazil to treat malaria with drug in doses 
that are based on age groups instead of patient weight. However, 
this can lead to insufficient quantities of drug delivery and hence 
to clinical relapses that may erroneously be confused with drug 
resistance or reinfection. This study reports two patients with relapses 
of malaria caused by Plasmodium vivax. Both patients weighed over 
70kg and were initially treated with standard-dose regimens of 
antimalarial agents based on age group.
Case 1 
A 51 year-old male businessman with a body mass index (BMI) 
of 32.5kg/m2, resident in Ceilândia (DF) traveled to Ariquemes 
(RO) in July 2004, and on returning to DF showed symptoms of 
malaria. On July 22nd, 2004, a blood smear revealed P. vivax (+++), 
with 10,651 parasites/mm3, and the patient was treated with 
10 tablets of chloroquine for 3 days (4 tablets of 150mg of active 
base on day 1, followed by 3 tablets on days 2 and 3), supplemented 
with 14 tablets of primaquine for 7 days (2 tablets of 15mg per day). 
On March 8th, 2004, the blood smear was negative, but it became 
positive again on August 26th, 2004. The same initial treatment 
regimen was administered and follow-up blood smears on 08/30, 
09/16, 9/24 and 10/18 were negative. However, on October 25th, 
2004, the test became positive again, with 11,308 parasites/mm3, 
and the patient was then treated with four tablets of mefloquine, 
250mg (single dose) and 14 tablets of primaquine for 7 days (2 
tablets 15mg daily). Five successive blood smears were negative, 
but in December 15th, 2004, the patient was positive again. The first 
treatment regimen was reintroduced, followed by two tablets of 
chloroquine weekly administered for 90 days. The ten following blood 
smears were negative until April 28th, 2005, when the test became 
positive once again and the patient was treated with 10 tablets of 
chloroquine for 3 days followed by 14 tablets of primaquine for 14 
days. Six successive blood smears were negative; however, on July 
14th, 2005, parasitemia reappeared. A new treatment regimen was 
administered with 10 tablets of chloroquine for 3 days, followed by 
21 tablets of primaquine for 21 days, and treatment was continued 
with 2 tablets of chloroquine weekly administered for 90 days. Since 
then, eleven blood smears performed up to January 1st, 2006 were 
negative. Throughout the monitoring period, the patient remained in 
the Federal District, an area not considered endemic for malaria. 
Case 2
A 51 year-old male lawyer, farmer and artist, residing in Lago 
Sul (DF) and whose BMI was 30.4 kg/m2, traveled to Sao Felix do 
Xingu (MT) in early September 2004. On September 9th, 2004, 
when he was in Palmas (TO), he was diagnosed with vivax malaria 
and standard treatment was proposed with 10 tablets of chloroquine 
for 3 days (4 tablets of 150mg of active base on day 1, followed by 3 
tablets on days 2 and 3), supplemented with 14 tablets of primaquine 
for 7 days (2 tablets of 15mg per day). Returning to Brasília, he 
presented malaria relapse in 10/20 and was treated with the previous 
regimen. The following blood smears were negative, but parasitemia 
recurred on December 21st, 2004 and the patient was treated with 
four tablets of mefloquine and 14 tablets of primaquine for 7 days. 
The following five blood smears were negative; however, the test 
was positive on February 17th, 2005 and the patient was treated with 
the same regimen of antimalarial drugs, followed by two tablets of 
chloroquine weekly administered for 90 days. The following blood 
smears in February, March and April were negative. However, the 
patient proved positive parasitemia again in September 16th, 2005. 
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Once more, the patient was treated with 10 tablets of chloroquine for 
3 days followed by one tablet of primaquine daily administered for 
21 days, continuing treatment with 2 tablets of chloroquine weekly 
administered for 90 days. The last eight blood smears, up to January 
6th, 2006, were negative. 
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forms and prevents relapses by eliminating hypnozoite forms2,3. A 
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to asexual forms of P. vivax to primaquine5 is an emerging public 
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remains first line treatment of vivax malaria. In these reported cases, 
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successful response to the second attempt at treatment with the 
same drugs. Chemical deterioration of the administered drug is 
unlikely, because its quality is assured by the Ministry of Health and 
by appropriate storage conditions. 
Uncomplicated vivax malaria is treated in Brazil with standard 
doses of drugs according to age group. Longer regimens with 
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relapse7. In the cases reported here, the doses chosen were those 
recommended for patients weighing 50kg or greater, which appears 
to be insufficient. While several studies have shown the deleterious 
effect of malnutrition on malaria infection, sometimes determining 
growth restriction of children in endemic areas, sometimes worsening 
the prognosis of the disease8, the relationship between malaria and 
obesity is poorly defined. The antimalarial treatment of obese patients 
based on doses equivalent to those of patients weighing 50kg has 
proven to be subtherapeutic. In order to correct this failure, the 
treatment standards established by the Ministry of Health already 
include recommendations to correct the dose of antimalarial drugs 
for patients over 70kg9. In cases of malaria recurrence, a 50% to 100% 
increase in the initial dose of primaquine is recommended10.
